38 related articles for article (PubMed ID: 21455800)
21. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma.
Saigal B; Glisson BS; Johnson FM
Anticancer Drugs; 2008 Jun; 19(5):465-75. PubMed ID: 18418213
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules.
Wasylyk C; Zheng H; Castell C; Debussche L; Multon MC; Wasylyk B
Cancer Res; 2008 Mar; 68(5):1275-83. PubMed ID: 18316589
[TBL] [Abstract][Full Text] [Related]
23. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Mahaffey CM; Davies AM; Lara PN; Pryde B; Holland W; Mack PC; Gumerlock PH; Gandara DR
Clin Lung Cancer; 2007 Nov; 8(9):548-53. PubMed ID: 18186959
[TBL] [Abstract][Full Text] [Related]
24. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
Christensen JG
Ann Oncol; 2007 Sep; 18 Suppl 10():x3-10. PubMed ID: 17761721
[TBL] [Abstract][Full Text] [Related]
25. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Li T; Ling YH; Goldman ID; Perez-Soler R
Clin Cancer Res; 2007 Jun; 13(11):3413-22. PubMed ID: 17545550
[TBL] [Abstract][Full Text] [Related]
26. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling.
Wan X; Shen N; Mendoza A; Khanna C; Helman LJ
Neoplasia; 2006 May; 8(5):394-401. PubMed ID: 16790088
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel for treatment of solid tumours: a systematic review of clinical data.
Montero A; Fossella F; Hortobagyi G; Valero V
Lancet Oncol; 2005 Apr; 6(4):229-39. PubMed ID: 15811618
[TBL] [Abstract][Full Text] [Related]
28. [Tyrosine kinase receptor-mediated signal transduction and cancer treatment].
Zhu XF; Liu ZC; Zeng YX
Yao Xue Xue Bao; 2002 Mar; 37(3):229-34. PubMed ID: 12579770
[No Abstract] [Full Text] [Related]
29. Cancer statistics, 2003.
Jemal A; Murray T; Samuels A; Ghafoor A; Ward E; Thun MJ
CA Cancer J Clin; 2003; 53(1):5-26. PubMed ID: 12568441
[TBL] [Abstract][Full Text] [Related]
30. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Mendel DB; Laird AD; Xin X; Louie SG; Christensen JG; Li G; Schreck RE; Abrams TJ; Ngai TJ; Lee LB; Murray LJ; Carver J; Chan E; Moss KG; Haznedar JO; Sukbuntherng J; Blake RA; Sun L; Tang C; Miller T; Shirazian S; McMahon G; Cherrington JM
Clin Cancer Res; 2003 Jan; 9(1):327-37. PubMed ID: 12538485
[TBL] [Abstract][Full Text] [Related]
31. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
[TBL] [Abstract][Full Text] [Related]
32. Estimating the world cancer burden: Globocan 2000.
Parkin DM; Bray F; Ferlay J; Pisani P
Int J Cancer; 2001 Oct; 94(2):153-6. PubMed ID: 11668491
[No Abstract] [Full Text] [Related]
33. Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity.
Liebmann C
Cell Signal; 2001 Nov; 13(11):777-85. PubMed ID: 11583913
[TBL] [Abstract][Full Text] [Related]
34. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.
Sweeney CJ; Miller KD; Sissons SE; Nozaki S; Heilman DK; Shen J; Sledge GW
Cancer Res; 2001 Apr; 61(8):3369-72. PubMed ID: 11309294
[TBL] [Abstract][Full Text] [Related]
35. Angiogenesis in cancer, vascular, rheumatoid and other disease.
Folkman J
Nat Med; 1995 Jan; 1(1):27-31. PubMed ID: 7584949
[TBL] [Abstract][Full Text] [Related]
36. Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
Wang D; Jiang Z; Zhang L
Med Oncol; 2012 Jun; 29(2):600-6. PubMed ID: 21455800
[TBL] [Abstract][Full Text] [Related]
37. The current status and evolving role of sunitinib in non-small cell lung cancer.
Socinski MA
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S119-23. PubMed ID: 18520293
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
